67 related articles for article (PubMed ID: 16466998)
1. Target practice: figuring out which, when, and why to use systemic therapies for metastatic colon cancer.
Holen KD
Cancer Invest; 2006 Feb; 24(1):98-105. PubMed ID: 16466998
[TBL] [Abstract][Full Text] [Related]
2. Systemic therapy for advanced or metastatic colorectal cancer: National Comprehensive Cancer Network guidelines for combining anti-vascular endothelial growth factor and anti-epidermal growth factor receptor monoclonal antibodies with chemotherapy.
Engstrom PF;
Pharmacotherapy; 2008 Nov; 28(11 Pt 2):18S-22S. PubMed ID: 18980548
[TBL] [Abstract][Full Text] [Related]
3. Systemic treatment options for patients with refractory adult-type sarcoma beyond anthracyclines.
Hartmann JT
Anticancer Drugs; 2007 Mar; 18(3):245-54. PubMed ID: 17264755
[TBL] [Abstract][Full Text] [Related]
4. Sequencing therapies: the role of targeted agents in metastatic colorectal cancer.
Oestreicher P
ONS Connect; 2007; 22(8 Suppl):37-8. PubMed ID: 17824557
[No Abstract] [Full Text] [Related]
5. Combining targeted therapies and drugs with multiple targets in the treatment of NSCLC.
Maione P; Gridelli C; Troiani T; Ciardiello F
Oncologist; 2006 Mar; 11(3):274-84. PubMed ID: 16549812
[TBL] [Abstract][Full Text] [Related]
6. First- and second-line therapy of metastatic colorectal cancer.
Terstriep S; Grothey A
Expert Rev Anticancer Ther; 2006 Jun; 6(6):921-30. PubMed ID: 16761936
[TBL] [Abstract][Full Text] [Related]
7. An update on treatment advances for the first-line therapy of metastatic colorectal cancer.
Lee JJ; Chu E
Cancer J; 2007; 13(5):276-81. PubMed ID: 17921724
[TBL] [Abstract][Full Text] [Related]
8. Biologic therapy of breast cancer: focus on co-inhibition of endocrine and angiogenesis pathways.
Roy V; Perez EA
Breast Cancer Res Treat; 2009 Jul; 116(1):31-8. PubMed ID: 19101790
[TBL] [Abstract][Full Text] [Related]
9. Advances in chemotherapy against advanced or metastatic colorectal cancer.
Omura K
Digestion; 2008; 77 Suppl 1():13-22. PubMed ID: 18204257
[TBL] [Abstract][Full Text] [Related]
10. Multitargeted inhibitors in lung cancer: new clinical data.
Bar J; Herbst RS; Onn A
Clin Lung Cancer; 2008; 9 Suppl 3():S92-9. PubMed ID: 19419930
[TBL] [Abstract][Full Text] [Related]
11. Fluoropyrimidine resistance in colon cancer.
Gorlick R; Banerjee D
Expert Rev Anticancer Ther; 2002 Aug; 2(4):409-16. PubMed ID: 12647984
[TBL] [Abstract][Full Text] [Related]
12. From molecular biology to targeted therapies for hepatocellular carcinoma: the future is now.
Pang RW; Poon RT
Oncology; 2007; 72 Suppl 1():30-44. PubMed ID: 18087180
[TBL] [Abstract][Full Text] [Related]
13. Germline polymorphisms may act as predictors of response to preoperative chemoradiation in locally advanced T3 rectal tumors.
Spindler KL; Nielsen JN; Lindebjerg J; Jakobsen A
Dis Colon Rectum; 2007 Sep; 50(9):1363-9. PubMed ID: 17661145
[TBL] [Abstract][Full Text] [Related]
14. Relationships of insulin-like growth factor-1 receptor and epidermal growth factor receptor expression to clinical outcomes in patients with colorectal cancer.
Takahari D; Yamada Y; Okita NT; Honda T; Hirashima Y; Matsubara J; Takashima A; Kato K; Hamaguchi T; Shirao K; Shimada Y; Shimoda T
Oncology; 2009; 76(1):42-8. PubMed ID: 19033715
[TBL] [Abstract][Full Text] [Related]
15. Integrating targeted agents into therapeutic regimens for patients with resectable colorectal cancer.
Marshall JL
Clin Colorectal Cancer; 2008 Dec; 7 Suppl 2():S63-6. PubMed ID: 19064409
[TBL] [Abstract][Full Text] [Related]
16. Bevacizumab: new drug. Metastatic colorectal cancer: good in theory, not in practice.
Prescrire Int; 2006 Jun; 15(83):94-7. PubMed ID: 16764097
[TBL] [Abstract][Full Text] [Related]
17. Development of targeted therapies in advanced gastric cancer: promising exploratory steps in a new era.
Wagner AD; Moehler M
Curr Opin Oncol; 2009 Jul; 21(4):381-5. PubMed ID: 19412098
[TBL] [Abstract][Full Text] [Related]
18. Final results of a randomised phase III study on adjuvant chemotherapy with 5 FU and levamisol in colon and rectum cancer stage II and III by the Norwegian Gastrointestinal Cancer Group.
Dahl O; Fluge Ø; Carlsen E; Wiig JN; Myrvold HE; Vonen B; Podhorny N; Bjerkeset O; Eide TJ; Halvorsen TB; Tveit KM;
Acta Oncol; 2009; 48(3):368-76. PubMed ID: 19242829
[TBL] [Abstract][Full Text] [Related]
19. Resection of hepatic metastasis after 5-fluorouracil and cofactor for colon cancer.
Costantini CL; Reid TR; Bouvet M
Hepatogastroenterology; 2009; 56(91-92):645-9. PubMed ID: 19621672
[TBL] [Abstract][Full Text] [Related]
20. Adjuvant therapy of colon cancer: current status and future directions.
Chung KY; Saltz LB
Cancer J; 2007; 13(3):192-7. PubMed ID: 17620769
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
